Partnering at Boehringer Ingelheim Canada
Partnering at Boehringer Ingelheim Canada
Search
Partnering at Boehringer Ingelheim Canada
Partnering at Boehringer Ingelheim Canada
Partnering-In-PAIN
Sustainable Development - Our Commitment
Our Commitment
Retinal Diseases
Retinal Diseases
The Research Process
Science and Innovation - Animal Health Innovation - Parasiticides
Anna Dieckmann
Anna Dieckmann talks about professional fulfilment and possibilities for the future in her role in Information Technology.
Mental Disorders
Mental Disorders
Albertans living with chronic conditions benefit from home monitoring
Albertans living with chronic conditions benefit from home monitoring
Innovative health projects impact thousands of Indigenous Peoples in Canada
Innovative health projects impact thousands of Indigenous Peoples in Canada
New analytical tool helps optimize patient care
New analytical tool helps optimize patient care
The Type 2 Spark Innovation Challenge
The Type 2 Spark Innovation Challenge
Virtual care pharmacy services offered in Alberta long-term care facilities
Virtual care pharmacy services offered in Alberta long-term care facilities
Tackling care gaps in respiratory diseases in Alberta
Tackling care gaps in respiratory diseases in Alberta
Accessible Customer Service Policy
Accessible Customer Service Policy
Business Ethics
The ethical principles that have guided Boehringer Ingelheim for 130 years created a culture of corporate and social responsibility and commitment.
Effective management practices for parasite control in cattle
Effective management practices for parasite control in cattle
Health Canada approves NexGard® and NexGard Spectra™ for the reduction of Lyme disease
Health Canada approves NexGard® and NexGard Spectra™ for the reduction of Lyme disease
First Half of 2022: Boehringer Ingelheim continues growth pace and strengthens research pipeline
Growing late-stage research pipeline, addressing areas of high unmet medical need Pipeline includes areas such as rare skin disease, pulmonary fibrosis, oncology and central nervous system disease Net sales rise currency-adjusted by 9.5 percent to 11.
Indigenous Peoples living with diabetes is the focus of four new health pilot projects in Ontario, Nunavut, Alberta, and Manitoba
Indigenous Peoples living with diabetes is the focus of four new health pilot projects in Ontario, Nunavut, Alberta, and Manitoba
Sunnybrook collaborates with Boehringer Ingelheim Canada to enhance care for complex cardiovascular patients
Sunnybrook collaborates with Boehringer Ingelheim Canada to enhance care for complex cardiovascular patients
Boehringer Ingelheim reaches more patients than ever in 2022 as innovative medicines drive growth
• Medicines reached a record 30 million people, driven by JARDIANCE® and OFEV® • R&D investments of 5 billion EUR, or 21 percent of net sales • Net sales rise 10.5 percent (currency adjusted), up strongly to 24.1 billion EUR
Introducing Ingelvac Provenza™ — Stop influenza A Virus in swine where it starts
Introducing Ingelvac Provenza™ — Stop influenza A Virus in swine where it starts
First half of 2023: Boehringer Ingelheim sees strong growth and expansion in key therapy areas
First half of 2023: Boehringer Ingelheim sees strong growth and expansion in key therapy areas
Collaboration key to meeting consumers’ expectations for better animal welfare
Collaboration key to meeting consumers’ expectations for better animal welfare